4 completed, 2 recruiting, 1 active not recruiting, 1 enrolling by invitation. 9 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 4, Recruiting 2, Active not recruiting 1, Enrolling by invitation 1, Terminated 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow Mucosal Melanoma: new trials by email Literature Review of Mucosal Melanoma trials Research Report on Mucosal Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors KUP-101A - Cutaneous Melanoma, Mucosal Melanoma | Phase 1 | Recruiting | Kupando GmbH | 21 | 2026-07-03 | 2026-08-12 |
| A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma [225Ac]Ac-A9-3408, [68Ga]Ga-A9T-3202 - Melanoma Metastatic, Uveal Melanoma, Metastatic | Phase 1 | Terminated | Alpha-9 Oncology USA Inc. | 5 | 2025-11-19 | 2026-08-31 |
| A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma AK104+Axitinib, AK112+Axitinib - Melanoma, Mucosal Melanoma | Phase 1 | Enrolling by invitation | Peking University Cancer Hospital & Institute | 60 | 2024-05-28 | 2026-07-13 |
| Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma TBio-4101, Cyclophosphamide, Fludarabine - Metastatic Melanoma, Unresectable Melanoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 17 | 2022-11-22 | 2026-04-02 |
| A Beta-only IL-2 ImmunoTherapY Study MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 / Phase 2 | Recruiting | Medicenna Therapeutics, Inc. | 160 | 2021-08-27 | 2026-10-13 |
| A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas RO7293583, Tocilizumab, Obinutuzumab - Cutaneous Melanoma, Uveal Melanoma | Phase 1 | Completed | Hoffmann-La Roche | 20 | 2020-10-28 | 2022-10-03 |
| A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Phase 1b: APG-115+pembrolizumab - Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma | Phase 1 / Phase 2 | Active not recruiting | Ascentage Pharma Group Inc. | 230 | 2018-08-29 | 2025-08-07 |
| Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 | Completed | Emory University | 25 | 2016-10-04 | 2026-03-09 |
| Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists Peptide Vaccine (LPV7) + Tetanus peptide, PolyICLC, Resiquimod - Melanoma, Metastatic Melanoma | Phase 1 / Phase 2 | Completed | Craig L Slingluff, Jr | 50 | 2014-05-01 | 2024-02-28 |
Melanoma (9) · Uveal Melanoma (5) · Carcinoma, Basal Cell (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Skin Neoplasms (2) · Brain Neoplasms (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1)
Neoplasms by Histologic Type (9) · Neoplasms by Site (9) · Neoplasms, Germ Cell and Embryonal (9) · Neoplasms, Nerve Tissue (9) · Neuroectodermal Tumors (9) · Neuroendocrine Tumors (9) · Nevi and Melanomas (9) · Skin Diseases (9) · Skin and Connective Tissue Diseases (9) · Neoplasms (7) · Skin Neoplasms (7) · Eye Diseases (5) · Eye Neoplasms (5) · Uveal Diseases (5) · Uveal Neoplasms (5)
pembrolizumab (3) · Interleukin-2 (2) · Adalimumab (1) · Cyclophosphamide (1) · Protein Subunit Vaccines (1) · Radiosurgery (1) · fludarabine (1) · fludarabine phosphate (1) · obinutuzumab (1) · resiquimod (1) · tocilizumab (1)
Alpha-9 Oncology USA Inc. (1) · Ascentage Pharma Group Inc. (1) · Craig L Slingluff, Jr (1) · Emory University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hoffmann-La Roche (1) · Kupando GmbH (1) · Medicenna Therapeutics, Inc. (1) · Peking University Cancer Hospital & Institute (1)
United States (6) · Australia (4) · Canada (2) · Spain (2) · Belgium (1) · China (1) · Denmark (1) · Germany (1) · Ireland (1) · Portugal (1) · South Korea (1) · Switzerland (1)
Amod Sarnaik, MD (1) · Arash Yavari, MBBS (1) · Craig L Slingluff, Jr., M.D. (1) · Jun Guo, MD (1) · Mohammad K. Khan, MD, PhD (1) · Nina Merchant (1) · Yifan Zhai, MD, PhD (1)
2023 (1), 2025 (1), P30CA138292 (1)